Long-term effect of glimepiride and rosiglitazone on non-conventional cardiovascular risk factors in metformin-treated patients affected by metabolic syndrome: A randomized, double-blind clinical trial

Journal of International Medical Research

Volumn 33, Issue 3, 2005, Pages 284-294

  Derosa, G ^a   Gaddi, A V ^b   Ciccarelli, L ^a   Fogari, E ^a   Ghelfi, M ^a   Ferrari, I ^a   Cicero, A F G ^b  

^a UNIVERSITY OF PAVIA   (Italy)

^b UNIVERSITY OF BOLOGNA   (Italy)

Author keywords

Biguanide; Diabetes; Glimepiride; Homocysteine; Lipoprotein(A); Metabolic syndrome; Metformin; Rosiglitazone

Indexed keywords

CHOLESTEROL; GLIMEPIRIDE; GLUCOSE; GLYCOSYLATED HEMOGLOBIN; HEMOGLOBIN A1C; HOMOCYSTEINE; INSULIN; LIPOPROTEIN A; METFORMIN; ROSIGLITAZONE;

ADULT; ARTICLE; BEHAVIOR MODIFICATION; BODY MASS; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIET RESTRICTION; DIET THERAPY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; EXPERIENCE; FEMALE; GLUCOSE HOMEOSTASIS; HUMAN; HYPERCHOLESTEROLEMIA; INSULIN RESISTANCE; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; METABOLIC SYNDROME X; MULTICENTER STUDY; NON INSULIN DEPENDENT DIABETES MELLITUS; POSTPRANDIAL STATE; RANDOMIZED CONTROLLED TRIAL; RISK FACTOR; TREATMENT OUTCOME; WEIGHT REDUCTION;

EID: 19644378491     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/147323000503300303     Document Type: Article

References (42)

1. American Diabetes Association: Clinical practice recommendations 2004. Diabetes Care 2004; 25 (Suppl 1): S1-S150.
2. Van Goal LF, De Leeuw IH: Rationale and options for combination therapy in the treatment of type 2 diabetes. Diabetologia 2003; 46 (Suppl 1): 44-50.
3. Riddle M: Combining sulfonylureas and other oral agents. Am J Med 2000; 108 (Suppl 6a): 15-22.
4. Vague P: Is metformin more than an oral hypoglycaemic agent? Diabetes Metab 2003; 29: 5-7.
5. Johnson JA, Majumdar SR, Simpson SH, Toth EL: Decreased mortality associated with the use of metformin compared with sulfonylurea monotherapy in type 2 diabetes. Diabetes Care 2002; 25: 2244-2248.
6. UK Prospective Diabetes Study (UKPDS) Group: Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes. Lancet 1998; 253: 854-865.
7. The Diabetes Prevention Program Research Group: Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N Engl J Med 2002; 346: 393-403.
8. McCall AL: Clinical review of glimepiride. Expert Opin Pharmacother 2001; 2: 699-713.
9. Stumvoll M: Thiazolidinediones - some recent developments. Expert Opin Investig Drugs 2003; 12: 1179-1187.
10. Herrmann W, Knapp JP: Hyperhomocysteinemia: a new risk factor for degenerative diseases. Clin Lab 2002; 48: 471-481.
11. Ghosh K: Thrombohaemorrhagic balance in diabetes mellitus. J Indian Med Assoc 2002; 100: 428-433.
12. Calverley DC, Hacker MR, Loda KA, Brass E, Buchanan TA, Tsao-Wei DD, et al: Increased platelet Fc receptor expression as a potential contributing cause of platelet hypersensitivity to collagen in diabetes mellitus. Br J Haematol 2003; 121: 139-142.
13. Sambola A, Osende J, Hathcock J, Degen M, Nemerson Y, Fuster V, et al: Role of risk factors in the modulation of tissue factor activity and blood thrombogenicity. Circulation 2003; 107: 973-977.
14. Derosa G, Cicero AF, Gaddi A, Mugellini A, Ciccarelli L, Fogari R: The effect of L-carnitine on plasma lipoprotein(a) levels in hypercholesterolemic patients with type 2 diabetes mellitus. Clin Ther 2003; 25: 1429-1439.
15. Abbink EJ, Pickkers P, Jansen van Rosendaal A, Lutterman JA, Tack CJ, Russel FG, et al: Vascular effects of glibenclamide vs. glimepiride and metformin in type 2 diabetic patients. Diabet Med 2002; 19: 136-143.
16. Jones TA, Sautter M, Van Goal LF, Jones NP: Addition of rosiglitozone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Diabetes Obes Metab 2003; 5: 163-170.
17. American Diabetes Association: Screening for type 2 diabetes. Diabetes Care 2004; 27 (Suppl 1): S11-S14.
18. World Health Organization: Obesity: Preventing and Managing the Global Epidemic. Report of WHO Consultation on Obesity. Geneva: World Health Organization, 1997.
19. 1999 World Health Organization - International Society of Hypertension Guidelines for the Management of Hypertension. Guidelines Sub-Committee. Blood Press Suppl 1999; 1: 9-43.
20. Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults: Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA 2001; 285: 2486-2497.
21. American Diabetes Association: Nutrition recommendations and principles for people with diabetes mellitus (Position Statement). Diabetes Care 2001; 24: S44-S47.
22. Matthews DR, Hosker JP, Rudenski AS, Naylor BA, Treacher DF, Turner RC: Homeostasis model assessment: insulin resistance and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419.
23. Bunn HF, Gabbay HK, Gallop PM: The glycosylation of haemoglobin: relevance to diabetes mellitus. Science 1978; 200: 21-27.
24. European Diabetes Policy Group: A desktop guide to type 2 diabetes mellitus. Diabet Med 1999; 16: 716-730.
25. Heding LG: Determination of total serum insulin (IRI) in insulin-treated diabetic patients. Diabetologia 1972; 8: 260-266.
26. Scanu AM, Scandiani L: Lipoprotein(a): structure, biology, and clinical relevance. Adv Intern Med 1991; 36: 249-270.
27. Araki A, Sako Y: Determination of free and total homocysteine in human plasma by high performance liquid chromatography with fluorescence detection. J Chromatography 1987; 422: 43-52.
28. Winer BJ: Statistical Principles in Experimental Design, 2nd edn. New York: McGraw-Hill, 1971.
29. Marcovina SM, Koschinsky ML: Lipoprotein(a) as a risk factor for coronary artery disease. Am J Cardiol 1998; 82: 57-66.
30. Glader CA, Birgander LS, Stendlund H, Dahlen GH: Is lipoprotein(a) a predictor for survival in patients with established coronary artery disease? Results from a prospective patient cohort study in northern Sweden. J Intern Med 2002; 252: 27-35.
31. Peltier M, Iannetta Peltier MC, Sarano ME, Lesbre JP, Colas JL, Tribouilloy CM: Elevated serum lipoprotein(a) level is an independent marker of severity of thoracic aortic atherosclerosis. Chest 2002; 1212: 1589-1594.
32. Misirli H, Somay G, Ozbal N, Yasar Erenoglu N: Relation of lipid and lipoprotein(a) to ischaemic stroke. J Clin Neurosci 2002; 9: 127-132.
33. Nawawi HM, Muhajir M, Kian YC, Mohamud WN, Yusoff K, Khalid BA: Type of diabetes and waist-hip ratio are important determinants of serum lipoprotein(a) levels in diabetic patients. Diabetes Res Clin Pract 2002; 56: 221-227.
34. Maca TH, Ahmadi R, Derfler K, Ehringer H, Gschwandtner ME, Horl W, et al: Influence of lipoprotein(a) on restenosis after femoropopliteal percutaneous transluminal angioplasty in type 2 diabetic patients. Diabet Med 2002; 19: 300-306.
35. Tarkun I, Cetinarslan B, Canturk Z: Lipoprotein(a) concentrations in patients with type 2 diabetes mellitus without cardiovascular disease: relationship to metabolic parameters and diabetic complications. Nutr Metab Cardiovasc Dis 2002; 12: 127-131.
36. Mennen LI, de Courcy GP, Guilland JC, Ducros V, Bertrais S, Nicolas JP, et al: Homocysteine, cardiovascular disease risk factors, and habitual diet in the French Supplementation with Antioxidant Vitamins and Minerals Study. Am J Clin Nutr 2002; 76: 1279-1289.
37. Mattson MP, Haberman F: Folate and homocysteine metabolism: therapeutic targets in cardiovascular and neurodegenerative disorders. Curr Med Chem 2003; 10: 1923-1929.
38. Schnyder G, Roffi M, Flammer Y, Pin R, Eberli FR, Meier B, et al: Effect of homocysteine-lowering therapy on restenosis after percutaneous coronary intervention for narrowings in small coronary arteries. Am J Cardiol 2003; 91: 1265-1269.
39. Derosa G, Mugellini A, Ciccarelli L, Crescenzi G, Fogari R: Comparison between repaglinide and glimepiride in patients with type 2 diabetes mellitus: a one-year, randomized, double-blind assessment of metabolic parameters and cardiovascular risk factors. Clin Ther 2003; 25: 472-484.
40. Ko SH, Song KH, Ahn YB, Yoo SJ, Son HS, Yoon KH, et al: The effect of rosiglitazone on serum lipoprotein(a) levels in Korean patients with type 2 diabetes mellitus. Metabolism 2003; 52: 731-734.
41. Koschinsky ML, Marcovina SM: The relationship between lipoprotein(a) and the complications of diabetes mellitus. Acta Diabetol 2003; 40: 65-76.
42. Marcovina SM, Koschinsky ML: Evaluation of lipoprotein(a) as a prothrombotic factor: progress from bench to bedside. Curr Opin Lipidol 2003; 14: 361-366.